BioSpace News Archive

Fullpower Technologies, in collaboration with Stanford Sleep Medicine and UCSF Department of Psychiatry and Behavioral Sciences, presented two major studies at the SLEEP 2024 conference, furthering our understanding of sleep fragmentation and heart rate variability (HRV) during sleep.

Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced that it will release first quarter 2024 results and corporate update on Wednesday, June 12, 2024.

Merck, known as MSD outside of the United States and Canada, announced that Robert M. Davis, chairman and chief executive officer, and Dr. Dean Y. Li, executive vice president and president, Merck Research Laboratories, are scheduled to participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024, at 10:00 a.m. EDT.

Mallinckrodt plc, a global specialty pharmaceutical company, announced the presentation of three posters on TERLIVAZ® for injection in patients with hepatorenal syndrome with rapid reduction in kidney function1 at the 2024 European Association for the Study of the Liver Congress taking place in Milan, Italy from June 5-8, 2024.

STAAR Surgical to Participate in Goldman Sachs 45th Annual Global Healthcare Conference.

Precision BioSciences, Inc. today announced that the company will present preclinical data for its PBGENE-HBV clinical candidate at the European Association for the Study of the Liver Congress (EASL), highlighting the differentiated ability of ARCUS to make efficient, durable, and targeted elimination edits.

Axsome Therapeutics, Inc. today announced that it has entered into a settlement agreement with Unichem Laboratories Ltd. (Unichem) resolving patent litigation related to Axsome’s product Sunosi ® (solriamfetol).

Avinger, Inc. today announced that it will increase focus on its coronary artery disease program, where it is developing an innovative new image-guided therapeutic system to address unmet coronary market needs, while reducing the operating costs of its peripheral artery disease business.

Envisagenics, an AI-driven revenue generating biotechnology company focused on discovery and development of novel RNA splicing therapeutics, today announced a Series B fundraising round with participation from existing investors Third Kind Venture Capital, Empire State Development and Red Cell Partners, and new strategic investor Bristol Myers Squibb (NYSE: BMY).

Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will speak at the Goldman Sachs 45th Annual Global Healthcare Conference.